January 17th 2025
Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Medicines top consumers' counterfeit concern list
November 27th 2009Five per cent of consumers across five European countries suspect they may have received a counterfeit prescription and 1% believe that they definitely have, according to research conducted by ICM on behalf of patient safety communications company Aegate (UK).
EMEA reaffirms safety of pandemic vaccines
November 27th 2009After further reviewing data on the H1N1 pandemic vaccines approved in Europe, the EMEA has reaffirmed their balance of benefits and risks in the context of the current H1N1 influenza pandemic. Additionally, the World Health Organization (WHO) has issued an update on the H1N1 situation in Europe.
European Consumers Call for Tougher Counterfeit Measures
November 25th 2009Five percent of consumers across five European countries suspect they may have received a counterfeit prescription, and 1% believe that they definitely have, according to research conducted by ICM on behalf of patient safety communications company Aegate (UK).
Right first time drug manufacture
November 20th 2009Engineers at a UK university claim to have developed technology that can be used in existing chemical reactors to ensure right first time drug crystal formation, which is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' operations.